Anal Cancer - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 198
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A0BDFD902DEEN
Leaflet:

Download PDF Leaflet

Anal Cancer - Pipeline Review, H2 2017
Anal Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2017, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 10, 3 and 4 respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Anal Cancer - Overview
Anal Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Anal Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Anal Cancer - Companies Involved in Therapeutics Development
Advaxis Inc
Amgen Inc
Atara Biotherapeutics Inc
Bayer AG
BeiGene Ltd
Eli Lilly and Company
Immunovaccine Inc
ISA Pharmaceuticals BV
Merck & Co Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
PDS Biotechnology Corp
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Anal Cancer - Drug Profiles
ATA-368 - Drug Profile
axalimogene filolisbac - Drug Profile
axalimogene filolisbac second generation - Drug Profile
BAY-1125976 - Drug Profile
BGBA-317 - Drug Profile
cisplatin - Drug Profile
CUE-101 - Drug Profile
DPXE-7 - Drug Profile
ISA-101 - Drug Profile
nivolumab - Drug Profile
paclitaxel albumin free - Drug Profile
panitumumab - Drug Profile
PDS-0101 - Drug Profile
pembrolizumab - Drug Profile
prexasertib - Drug Profile
TLC-388 - Drug Profile
Vicoryx - Drug Profile
Anal Cancer - Dormant Projects
Anal Cancer - Discontinued Products
Anal Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Anal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Anal Cancer - Pipeline by Advaxis Inc, H2 2017
Anal Cancer - Pipeline by Amgen Inc, H2 2017
Anal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Anal Cancer - Pipeline by Bayer AG, H2 2017
Anal Cancer - Pipeline by BeiGene Ltd, H2 2017
Anal Cancer - Pipeline by Eli Lilly and Company, H2 2017
Anal Cancer - Pipeline by Immunovaccine Inc, H2 2017
Anal Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017
Anal Cancer - Pipeline by Merck & Co Inc, H2 2017
Anal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Anal Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017
Anal Cancer - Pipeline by PDS Biotechnology Corp, H2 2017
Anal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Anal Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Anal Cancer - Dormant Projects, H2 2017
Anal Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Anal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Advaxis Inc
Amgen Inc
Atara Biotherapeutics Inc
Bayer AG
BeiGene Ltd
Eli Lilly and Company
Immunovaccine Inc
ISA Pharmaceuticals BV
Merck & Co Inc
Ono Pharmaceutical Co Ltd
Oryx GmbH & Co KG
PDS Biotechnology Corp
Sun Pharma Advanced Research Company Ltd
Taiwan Liposome Company Ltd
Skip to top


Anal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 183 pages
Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Rectal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 130 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 2,000.00 Apr, 2016 · 109 pages

Ask Your Question

Anal Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: